France
GMT Science is a biotechnology startup headquartered in France, founded in 2020, with the slogan "Bringing microbiomics to the clinic." The company aims to improve the clinical management of chronic diseases through reliable, clinical-grade gut microbiome analysis.
GMT Science recognizes the growing list of medical conditions, such as liver and bowel diseases, diabetes, obesity, mental disorders, and cancer, which have shown changes in the composition and functionality of the gut microbiota. This presents an opportunity to use microbiome-based biomarkers in clinical management.
However, the lack of reliable solutions for assessing the microbiome of patients for disease prevention, monitoring, and prognosis is a pressing issue for clinicians. This is where GMT Science enters the picture, leveraging standardized analytical procedures, high-quality quantitative metagenomics, and proprietary AI-based algorithms to offer robust and reproducible microbiome analysis to medical laboratories. Their microbiome analysis software is a CE-marked medical device for in vitro diagnostic.
By providing precise metrics and reference values to medical labs, GMT Science enables physicians to incorporate the patient’s microbiome into their clinical practice, thereby enhancing the potential for tailored and effective treatment approaches. While specific details about the company's last investment and associated investors are not available at the moment, the industry focus of GMT Science encompasses biotechnology and health care. As the field of microbiome analysis and its clinical applications continues to expand, GMT Science presents an intriguing prospect for investors seeking opportunities at the intersection of biotechnology and healthcare innovation.
